Effect of zoledronic acid on bone metabolism in prostate cancer (T3NXMO) patients on the androgen deprivation

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：205 / 205
页数：1
相关论文
共 50 条
  • [21] Androgen-Deprivation Bone Loss in Patients With Prostate Cancer
    Abarado, Cynthia
    Mahon, Suzanne M.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (02) : 191 - 198
  • [22] Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer
    Weinfurt, KP
    Anstrom, KJ
    Castel, LD
    Schulman, KA
    Saad, F
    ANNALS OF ONCOLOGY, 2006, 17 (06) : 986 - 989
  • [23] Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer - Editorial comment
    Saad, Fred
    JOURNAL OF UROLOGY, 2006, 176 (03): : 978 - 978
  • [24] Titration of Dosage for the Protective Effect of Zoledronic Acid on Bone Loss in Patients Submitted to Androgen Deprivation Therapy due to Prostate Cancer: A Prospective Open-Label Study
    Rodrigues, Paulo
    Meler, Alex
    Hering, Flavio
    UROLOGIA INTERNATIONALIS, 2010, 85 (02) : 180 - 185
  • [25] Efficacy of Combined Androgen Blockade with Zoledronic Acid Treatment in Prostate Cancer with Bone Metastasis: The ZABTON-PC (Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer) Study
    Ueno, Satoru
    Mizokami, Atsushi
    Fukagai, Takashi
    Fujimoto, Naohiro
    Oh-Oka, Hitoshi
    Kondo, Yukihiro
    Arai, Gaku
    Ide, Hisamitsu
    Horie, Shigeo
    Ueki, Osamu
    Kawaguchi, Kouhei
    Shimamura, Masayoshi
    Orito, Matsuo
    Ishida, Takeyuki
    Ikeda, Daisuke
    Namiki, Mikio
    ANTICANCER RESEARCH, 2013, 33 (09) : 3837 - 3844
  • [26] Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: The Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer (Zabton-PC) study
    Ueno, Satoru
    Mizokami, Atsushi
    Fukagai, Takashi
    Fujimoto, Naohiro
    Ohoka, Hitoshi
    Kondo, Yukihiro
    Arai, Gaku
    Ide, Hisamitsu
    Namiki, Mikio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
    Smith, MR
    Eastham, J
    Gleason, DM
    Shasha, D
    Tchekmedyian, S
    Zinner, N
    JOURNAL OF UROLOGY, 2003, 169 (06): : 2008 - 2012
  • [28] The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).
    Hadji, P.
    Ziller, M.
    Maurer, T.
    Muth, M.
    Ruebel, A.
    May, C.
    Birkholz, K.
    Gschwend, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy
    Lang, Joshua M.
    Wallace, Marianne
    Becker, Jordan T.
    Eickhoff, Jens C.
    Buehring, Bjoern
    Binkley, Neil
    Staab, Mary Jane
    Wilding, George
    Liu, Glenn
    Malkovsky, Miroslav
    McNeel, Douglas G.
    CLINICAL GENITOURINARY CANCER, 2013, 11 (04) : 407 - 415
  • [30] BONE HEALTH IN THE PROSTATE CANCER PATIENTS RECEIVING ANDROGEN DEPRIVATION THERAPY
    Park, Nam Cheol
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 45 - 45
12345